Axicabtagene ciloleucel had durable responses, long-term survival, and consistent outcomes in patients with relapsed or ...

What’s the next step for this patient with a 4-year history of low-grade follicular lymphoma and who now has worsening lymphadenopathy and needs a nap at the end of every work day? Share on ...

SGR-1505 is under clinical development by Schrodinger and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase I drugs for Follicular Lymphoma have a 78% phase transition ...

chronic lymphocytic leukemia (CLL), follicular lymphoma, aggressive lymphoma, including diffuse large B-cell lymphoma (DLBCL), renal cell carcinoma, squamous cell carcinoma, cutaneous squamous cell ...

Monjuvi plus Revlimid and Rituxan demonstrated improved progression-free survival for patients with relapsed or refractory ...

Phototherapy involves the use of ultraviolet light for the treatment of skin disease and many dermatologists have phototherapy units in their offices. With these units, ultraviolet light of ...

Follicular lymphoma is considered an indolent disease, with long-term tumour control achieved by first-line ...

Researchers at the Mayo Clinic assessed the risk of cutaneous T ... subtypes of non-Hodgkin lymphoma (NHL), providing much-needed information. Risk stratification in follicular lymphoma relies ...

Dr. Sattva S. Neelapu discusses how the CAR-T therapy Yescarta impacts the quality of life of patients with R/R indolent non-Hodgkin lymphoma.

Liso-cel, a CD19-directed chimeric antigen receptor T-cell product, and mosunetuzumab, a CD20/CD3 bispecific antibody, are used to treat patients with relapsed/refractory follicular lymphoma.

Tafasitamab increased progression free survival by about 9 months when compared to placebo, according to recent study data.

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.